<p>Assenagon Asset Management S.A. 在最近向證券交易委員會提交的文件中表示，在第三季度將其在 Quest Diagnostics Incorporated (NYSE:DGX - 免費報告) 的持股減少了 73.2%。該機構投資者在季度內出售了 15,248 股後，持有該醫療研究公司 5,588 股股票。Assenagon Asset Management S.A. 在 Quest Diagnostics 的持股在最近一個季度末價值為 1,065,000 美元。</p>
<p>獲取 <strong>Quest Diagnostics</strong> 警報：</p>
<ul>
<li>Myriad Genetics 通過遺傳癌症檢測股價飆升</li>
</ul>
<p>其他對沖基金和機構投資者也買賣了該公司的股票。Oak Thistle LLC 在第三季度將其在 Quest Diagnostics 的持股增加了 119.7%。Oak Thistle LLC 目前擁有 3,833 股該醫療研究公司的股票，價值 730,000 美元，此前在上個季度又購買了 2,088 股。Aaron Wealth Advisors LLC 在第三季度購買了 Quest Diagnostics 的新頭寸，價值約為 1,452,000 美元。GAMMA Investing LLC 在第三季度將其在 Quest Diagnostics 的持股增加了 17.4%。GAMMA Investing LLC 目前擁有 3,511 股該醫療研究公司的股票，價值 669,000 美元，此前在上個季度又購買了 520 股。Hobart Private Capital LLC 在第三季度獲得了 Quest Diagnostics 的新股份，價值約為 564,000 美元。最後，Caldwell Trust Co 在第二季度購買了 Quest Diagnostics 的新股份，價值約為 346,000 美元。機構投資者持有該公司 88.06% 的股票。</p>
<h2>Quest Diagnostics 股價上漲 0.5%</h2>
<p>NYSE:DGX 的股票在週四以 175.92 美元開盤。該股票的 50 日簡單移動平均線為 182.79 美元，200 日簡單移動平均線為 179.89 美元。該公司的債務與股本比率為 0.71，速動比率為 1.04，流動比率為 1.13。Quest Diagnostics Incorporated 的一年低點為 148.70 美元，一年高點為 197.55 美元。該股票的市值為 195.7 億美元，市盈率為 20.65，市盈增長比率為 2.36，貝塔值為 0.62。</p>
<ul>
<li>LifeMD 股價因 GLP-1 業務增長而回升</li>
</ul>
<p>Quest Diagnostics (NYSE:DGX - 獲取免費報告) 最近於 10 月 21 日（星期二）公佈了其財報。該醫療研究公司報告季度每股收益為 2.60 美元，超出市場共識預期的 2.51 美元，超出 0.09 美元。Quest Diagnostics 的淨利潤率為 8.91%，股本回報率為 15.47%。該公司在本季度的收入為 28.2 億美元，而市場共識預期為 27.3 億美元。在去年同期，該公司每股收益為 2.30 美元。與去年同期相比，該公司的季度收入增長了 13.2%。Quest Diagnostics 已將其 2025 財年的指引設定為每股收益 9.760-9.840。股票分析師預測 Quest Diagnostics Incorporated 今年的每股收益將達到 9.7。</p>
<h2>Quest Diagnostics 宣佈分紅</h2>
<p>該公司最近還宣佈了一項季度分紅，將於 1 月 28 日（星期三）支付。1 月 13 日（星期二）登記的股東將獲得每股 0.80 美元的分紅。這相當於每年 3.20 美元的分紅，收益率為 1.8%。該分紅的除息日為 1 月 13 日（星期二）。Quest Diagnostics 的派息比率目前為 37.56%。</p>
<h2>內部買賣</h2>
<ul>
<li>Exact Sciences 正好滿足投資者的期望</li>
</ul>
<p>在其他消息中，SVP Mark E. Delaney 於 11 月 18 日（星期二）出售了 7,946 股該公司的股票。該股票的平均售價為 187.35 美元，總交易額為 1,488,683.10 美元。交易後，該高級副總裁直接持有 7,530 股該公司的股票，價值約為 1,410,745.50 美元。這筆交易代表其持股減少了 51.34%。該出售在向證券交易委員會提交的文件中披露，可通過 SEC 網站訪問。此外，SVP Michael E. Prevoznik 於 9 月 26 日（星期五）出售了 227 股該公司的股票。該股票的平均售價為 188.13 美元，總交易額為 42,705.51 美元。交易完成後，該高級副總裁直接持有 38,117 股該公司的股票，價值約為 7,170,951.21 美元。這代表其持股減少了 0.59%。該出售的披露信息可在 SEC 文件中找到。內部人士在過去九十天內出售了價值 12,631,382 美元的 65,998 股公司股票。內部人士持有該公司 8.16% 的股票。</p>
<h2>華爾街分析師預測增長</h2>
<p>幾位分析師最近對該公司進行了評論。Barclays 將 Quest Diagnostics 的目標價從 190.00 美元上調至 195.00 美元，並在 10 月 22 日（星期三）的研究報告中給予該股票 “持平” 評級。瑞銀集團將 Quest Diagnostics 的目標價從 180.00 美元上調至 190.00 美元，並在 10 月 17 日（星期五）的研究報告中給予該股票 “中性” 評級。Leerink Partners 將 Quest Diagnostics 的目標價從 203.00 美元上調至 210.00 美元，並在 10 月 21 日（星期二）的研究報告中給予該股票 “跑贏大盤” 評級。Weiss Ratings 在一份研究報告中重申了對 Quest Diagnostics 的 “買入（b-）” 評級。最後，Wall Street Zen 在 11 月 8 日（星期六）的報告中將 Quest Diagnostics 的評級從 “買入” 下調至 “持有”。一位分析師給予該股票 “強烈買入” 評級，七位分析師給予 “買入” 評級，十位分析師給予 “持有” 評級。根據 MarketBeat，該公司目前的共識評級為 “適度買入”，平均目標價為 197.27 美元。</p>
<p><strong>閲讀我們最新的 DGX 股票報告</strong></p>
<h2>Quest Diagnostics 簡介</h2>
<p>（免費報告）</p>
<p>Quest Diagnostics（紐約證券交易所代碼：DGX）是領先的診斷信息服務提供商，支持患者、醫生和醫療機構的臨牀決策。該公司運營着一個臨牀實驗室和患者服務中心的網絡，執行廣泛的實驗室測試和診斷分析，用於常規護理、疾病診斷、監測和篩查。</p>
<p>其服務涵蓋核心臨牀實驗室測試、解剖病理學、分子和基因組診斷、傳染病檢測和毒理學。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票，勝過 Quest Diagnostics</li>
<li>請勿刪除，立即閲讀</li>
<li>投資者警報：微型 “$3 AI 奇蹟股票” 即將騰飛</li>
<li>資本利得税是否可以扣除任何費用？</li>
<li>巴菲特、蓋茨和貝索斯悄悄拋售股票——原因在這裏</li>
<li>忘掉 AI 吧，這將是下一個重大科技突破</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPURHWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPURHWA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在 Quest Diagnostics 嗎？</h2>
<p>在考慮 Quest Diagnostics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄向客户推薦在更廣泛的市場注意到之前立即購買……而 Quest Diagnostics 並不在名單上。</p>
<p>雖然 Quest Diagnostics 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

奎斯特診療

<p>Assenagon Asset Management S.A. 在第三季度將其在奎斯特診療的股份減少了 73.2%，目前持有 5,588 股，價值 1,065,000 美元。其他機構投資者也調整了他們的持倉。奎斯特診療報告第三季度每股收益為 2.60 美元，超出預期，收入同比增長 13.2%。該公司宣佈每股季度分紅為 0.80 美元。在過去 90 天內，內部人士出售了價值 1263 萬美元的股份。該股票開盤價為 175.92 美元，市值為 195.7 億美元</p>

<p>Assenagon Asset Management S.A. decreased its position in shares of Quest Diagnostics Incorporated (NYSE:DGX - Free Report) by 73.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,588 shares of the medical research company's stock after selling 15,248 shares during the quarter. Assenagon Asset Management S.A.'s holdings in Quest Diagnostics were worth $1,065,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>Assenagon Asset Management S.A. 在最近向證券交易委員會提交的文件中表示，在第三季度將其在 Quest Diagnostics Incorporated (NYSE:DGX - 免費報告) 的持股減少了 73.2%。該機構投資者在季度內出售了 15,248 股後，持有該醫療研究公司 5,588 股股票。Assenagon Asset Management S.A. 在 Quest Diagnostics 的持股在最近一個季度末價值為 1,065,000 美元。</p>
</div><p>Get <strong>Quest Diagnostics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Quest Diagnostics</strong> 警報：</p>
</div><ul>
<li>Myriad Genetics Sees Stock Surge with Hereditary Cancer Tests</li>
</ul>
<div class="lb-trans"><ul>
<li>Myriad Genetics 通過遺傳癌症檢測股價飆升</li>
</ul>
</div><p>Other hedge funds and other institutional investors have also bought and sold shares of the company. Oak Thistle LLC grew its position in Quest Diagnostics by 119.7% during the 3rd quarter. Oak Thistle LLC now owns 3,833 shares of the medical research company's stock worth $730,000 after purchasing an additional 2,088 shares during the last quarter. Aaron Wealth Advisors LLC purchased a new position in Quest Diagnostics during the third quarter valued at approximately $1,452,000. GAMMA Investing LLC boosted its holdings in Quest Diagnostics by 17.4% during the third quarter. GAMMA Investing LLC now owns 3,511 shares of the medical research company's stock worth $669,000 after buying an additional 520 shares in the last quarter. Hobart Private Capital LLC acquired a new stake in shares of Quest Diagnostics during the 3rd quarter valued at about $564,000. Finally, Caldwell Trust Co purchased a new stake in shares of Quest Diagnostics in the second quarter valued at approximately $346,000. Institutional investors own 88.06% of the company's stock.</p>
<div class="lb-trans"><p>其他對沖基金和機構投資者也買賣了該公司的股票。Oak Thistle LLC 在第三季度將其在 Quest Diagnostics 的持股增加了 119.7%。Oak Thistle LLC 目前擁有 3,833 股該醫療研究公司的股票，價值 730,000 美元，此前在上個季度又購買了 2,088 股。Aaron Wealth Advisors LLC 在第三季度購買了 Quest Diagnostics 的新頭寸，價值約為 1,452,000 美元。GAMMA Investing LLC 在第三季度將其在 Quest Diagnostics 的持股增加了 17.4%。GAMMA Investing LLC 目前擁有 3,511 股該醫療研究公司的股票，價值 669,000 美元，此前在上個季度又購買了 520 股。Hobart Private Capital LLC 在第三季度獲得了 Quest Diagnostics 的新股份，價值約為 564,000 美元。最後，Caldwell Trust Co 在第二季度購買了 Quest Diagnostics 的新股份，價值約為 346,000 美元。機構投資者持有該公司 88.06% 的股票。</p>
</div><h2>Quest Diagnostics Stock Up 0.5%</h2>
<div class="lb-trans"><h2>Quest Diagnostics 股價上漲 0.5%</h2>
</div><p>Shares of NYSE:DGX opened at $175.92 on Thursday. The stock has a 50-day simple moving average of $182.79 and a 200-day simple moving average of $179.89. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.04 and a current ratio of 1.13. Quest Diagnostics Incorporated has a 1 year low of $148.70 and a 1 year high of $197.55. The stock has a market capitalization of $19.57 billion, a P/E ratio of 20.65, a PEG ratio of 2.36 and a beta of 0.62.</p>
<div class="lb-trans"><p>NYSE:DGX 的股票在週四以 175.92 美元開盤。該股票的 50 日簡單移動平均線為 182.79 美元，200 日簡單移動平均線為 179.89 美元。該公司的債務與股本比率為 0.71，速動比率為 1.04，流動比率為 1.13。Quest Diagnostics Incorporated 的一年低點為 148.70 美元，一年高點為 197.55 美元。該股票的市值為 195.7 億美元，市盈率為 20.65，市盈增長比率為 2.36，貝塔值為 0.62。</p>
</div><ul>
<li>LifeMD Shares Come Back to Life on GLP-1 Business Growth</li>
</ul>
<div class="lb-trans"><ul>
<li>LifeMD 股價因 GLP-1 業務增長而回升</li>
</ul>
</div><p>Quest Diagnostics (NYSE:DGX - Get Free Report) last announced its earnings results on Tuesday, October 21st. The medical research company reported $2.60 earnings per share for the quarter, beating the consensus estimate of $2.51 by $0.09. Quest Diagnostics had a net margin of 8.91% and a return on equity of 15.47%. The business had revenue of $2.82 billion during the quarter, compared to the consensus estimate of $2.73 billion. During the same period in the prior year, the firm earned $2.30 earnings per share. The business's quarterly revenue was up 13.2% compared to the same quarter last year. Quest Diagnostics has set its FY 2025 guidance at 9.760-9.840 EPS. Equities analysts forecast that Quest Diagnostics Incorporated will post 9.7 earnings per share for the current year.</p>
<div class="lb-trans"><p>Quest Diagnostics (NYSE:DGX - 獲取免費報告) 最近於 10 月 21 日（星期二）公佈了其財報。該醫療研究公司報告季度每股收益為 2.60 美元，超出市場共識預期的 2.51 美元，超出 0.09 美元。Quest Diagnostics 的淨利潤率為 8.91%，股本回報率為 15.47%。該公司在本季度的收入為 28.2 億美元，而市場共識預期為 27.3 億美元。在去年同期，該公司每股收益為 2.30 美元。與去年同期相比，該公司的季度收入增長了 13.2%。Quest Diagnostics 已將其 2025 財年的指引設定為每股收益 9.760-9.840。股票分析師預測 Quest Diagnostics Incorporated 今年的每股收益將達到 9.7。</p>
</div><h2>Quest Diagnostics Announces Dividend</h2>
<div class="lb-trans"><h2>Quest Diagnostics 宣佈分紅</h2>
</div><p>The company also recently announced a quarterly dividend, which will be paid on Wednesday, January 28th. Shareholders of record on Tuesday, January 13th will be paid a dividend of $0.80 per share. This represents a $3.20 dividend on an annualized basis and a yield of 1.8%. The ex-dividend date of this dividend is Tuesday, January 13th. Quest Diagnostics's payout ratio is presently 37.56%.</p>
<div class="lb-trans"><p>該公司最近還宣佈了一項季度分紅，將於 1 月 28 日（星期三）支付。1 月 13 日（星期二）登記的股東將獲得每股 0.80 美元的分紅。這相當於每年 3.20 美元的分紅，收益率為 1.8%。該分紅的除息日為 1 月 13 日（星期二）。Quest Diagnostics 的派息比率目前為 37.56%。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>內部買賣</h2>
</div><ul>
<li>Exact Sciences Serves Investors Exactly What They Wished For</li>
</ul>
<div class="lb-trans"><ul>
<li>Exact Sciences 正好滿足投資者的期望</li>
</ul>
</div><p>In other news, SVP Mark E. Delaney sold 7,946 shares of the firm's stock in a transaction on Tuesday, November 18th. The stock was sold at an average price of $187.35, for a total transaction of $1,488,683.10. Following the transaction, the senior vice president directly owned 7,530 shares of the company's stock, valued at approximately $1,410,745.50. This trade represents a 51.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through the SEC website. Also, SVP Michael E. Prevoznik sold 227 shares of the company's stock in a transaction that occurred on Friday, September 26th. The stock was sold at an average price of $188.13, for a total transaction of $42,705.51. Following the completion of the sale, the senior vice president directly owned 38,117 shares of the company's stock, valued at approximately $7,170,951.21. This represents a 0.59% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 65,998 shares of company stock valued at $12,631,382 in the last ninety days. Insiders own 8.16% of the company's stock.</p>
<div class="lb-trans"><p>在其他消息中，SVP Mark E. Delaney 於 11 月 18 日（星期二）出售了 7,946 股該公司的股票。該股票的平均售價為 187.35 美元，總交易額為 1,488,683.10 美元。交易後，該高級副總裁直接持有 7,530 股該公司的股票，價值約為 1,410,745.50 美元。這筆交易代表其持股減少了 51.34%。該出售在向證券交易委員會提交的文件中披露，可通過 SEC 網站訪問。此外，SVP Michael E. Prevoznik 於 9 月 26 日（星期五）出售了 227 股該公司的股票。該股票的平均售價為 188.13 美元，總交易額為 42,705.51 美元。交易完成後，該高級副總裁直接持有 38,117 股該公司的股票，價值約為 7,170,951.21 美元。這代表其持股減少了 0.59%。該出售的披露信息可在 SEC 文件中找到。內部人士在過去九十天內出售了價值 12,631,382 美元的 65,998 股公司股票。內部人士持有該公司 8.16% 的股票。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>Several analysts recently commented on the company. Barclays boosted their price target on Quest Diagnostics from $190.00 to $195.00 and gave the stock an &#34;equal weight&#34; rating in a research report on Wednesday, October 22nd. UBS Group raised their price objective on Quest Diagnostics from $180.00 to $190.00 and gave the stock a &#34;neutral&#34; rating in a research report on Friday, October 17th. Leerink Partners increased their price target on shares of Quest Diagnostics from $203.00 to $210.00 and gave the stock an &#34;outperform&#34; rating in a research report on Tuesday, October 21st. Weiss Ratings reissued a &#34;buy (b-)&#34; rating on shares of Quest Diagnostics in a research report on Monday. Finally, Wall Street Zen lowered Quest Diagnostics from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report on Saturday, November 8th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and ten have given a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $197.27.</p>
<div class="lb-trans"><p>幾位分析師最近對該公司進行了評論。Barclays 將 Quest Diagnostics 的目標價從 190.00 美元上調至 195.00 美元，並在 10 月 22 日（星期三）的研究報告中給予該股票 “持平” 評級。瑞銀集團將 Quest Diagnostics 的目標價從 180.00 美元上調至 190.00 美元，並在 10 月 17 日（星期五）的研究報告中給予該股票 “中性” 評級。Leerink Partners 將 Quest Diagnostics 的目標價從 203.00 美元上調至 210.00 美元，並在 10 月 21 日（星期二）的研究報告中給予該股票 “跑贏大盤” 評級。Weiss Ratings 在一份研究報告中重申了對 Quest Diagnostics 的 “買入（b-）” 評級。最後，Wall Street Zen 在 11 月 8 日（星期六）的報告中將 Quest Diagnostics 的評級從 “買入” 下調至 “持有”。一位分析師給予該股票 “強烈買入” 評級，七位分析師給予 “買入” 評級，十位分析師給予 “持有” 評級。根據 MarketBeat，該公司目前的共識評級為 “適度買入”，平均目標價為 197.27 美元。</p>
</div><p><strong>Read Our Latest Stock Report on DGX</strong></p>
<div class="lb-trans"><p><strong>閲讀我們最新的 DGX 股票報告</strong></p>
</div><h2>Quest Diagnostics Profile</h2>
<div class="lb-trans"><h2>Quest Diagnostics 簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Quest Diagnostics NYSE: DGX is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.</p>
<div class="lb-trans"><p>Quest Diagnostics（紐約證券交易所代碼：DGX）是領先的診斷信息服務提供商，支持患者、醫生和醫療機構的臨牀決策。該公司運營着一個臨牀實驗室和患者服務中心的網絡，執行廣泛的實驗室測試和診斷分析，用於常規護理、疾病診斷、監測和篩查。</p>
</div><p>Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.</p>
<div class="lb-trans"><p>其服務涵蓋核心臨牀實驗室測試、解剖病理學、分子和基因組診斷、傳染病檢測和毒理學。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Quest Diagnostics</li>
<li>Do not delete, read immediately</li>
<li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li>
<li>Can Any Expenses Be Deducted From Capital Gains Tax?</li>
<li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li>
<li>Forget AI, This Will Be the Next Big Tech Breakthrough</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過 Quest Diagnostics</li>
<li>請勿刪除，立即閲讀</li>
<li>投資者警報：微型 “$3 AI 奇蹟股票” 即將騰飛</li>
<li>資本利得税是否可以扣除任何費用？</li>
<li>巴菲特、蓋茨和貝索斯悄悄拋售股票——原因在這裏</li>
<li>忘掉 AI 吧，這將是下一個重大科技突破</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPURHWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=DGX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Quest Diagnostics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 Quest Diagnostics 嗎？</h2>
</div><p>Before you consider Quest Diagnostics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Quest Diagnostics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Quest Diagnostics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄向客户推薦在更廣泛的市場注意到之前立即購買……而 Quest Diagnostics 並不在名單上。</p>
</div><p>While Quest Diagnostics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Quest Diagnostics 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Assenagon 資產管理公司降低了其在奎斯特診療公司 $DGX 的持股比例